Related references
Note: Only part of the references are listed.Association Between Adverse Reactions to Allopurinol and Exposures to High Maintenance Doses Implications for Management of Patients Using Allopurinol
Tawatchai Paisansinsup et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2013)
Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010
Stephen P. Juraschek et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2013)
Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study
Seoyoung C. Kim et al.
ARTHRITIS CARE & RESEARCH (2013)
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2012)
GOSPEL: Prospective survey of gout in France. Part I: Design and patient characteristics (n=1003)
Frederic Liote et al.
JOINT BONE SPINE (2012)
Reduced Glomerular Function and Prevalence of Gout: NHANES 2009-10
Eswar Krishnan
PLOS ONE (2012)
2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
Dinesh Khanna et al.
ARTHRITIS CARE & RESEARCH (2012)
2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
Dinesh Khanna et al.
ARTHRITIS CARE & RESEARCH (2012)
Risk of end-stage renal disease associated with gout: a nationwide population study
Kuang-Hui Yu et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Using Allopurinol Above the Dose Based on Creatinine Clearance Is Effective and Safe in Patients With Chronic Gout, Including Those With Renal Impairment
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2011)
Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
Ratchadaporn Somkrua et al.
BMC MEDICAL GENETICS (2011)
Safety and Efficacy of Febuxostat Treatment in Subjects with Gout and Severe Allopurinol Adverse Reactions
Saima Chohan
JOURNAL OF RHEUMATOLOGY (2011)
HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency
Jae-Woo Jung et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
Mark McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Allelic and Haplotypic Diversity of HLA-A, -B, -C, and-DRB1 Genes in Koreans Defined by High-resolution DNA Typing
Hye Yoon Chung et al.
KOREAN JOURNAL OF LABORATORY MEDICINE (2010)
Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
Wichittra Tassaneeyakul et al.
PHARMACOGENETICS AND GENOMICS (2009)
Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate in Subjects With Hyperuricemia and Gout: A 28-Week, Phase III, Randomized, Double-Blind, Parallel-Group Trial
H. Ralph Schumacher et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
Sitna Halevy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Christine Lonjou et al.
PHARMACOGENETICS AND GENOMICS (2008)
Human leukocyte antigens and drug hypersensitivity
Wen-Hung Chung et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population
KW Lee et al.
TISSUE ANTIGENS (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices-modeling studies
MC Weinstein et al.
VALUE IN HEALTH (2003)
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
S Mallal et al.
LANCET (2002)
Relation between adverse events associated with allopurinol and renal function in patients with gout
J Vázquez-Mellado et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)
Share Paper
